Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹27,406 Cr
Revenue (TTM)
₹6,113 Cr
Net Profit (TTM)
₹847 Cr
ROE
7.8 %
ROCE
12 %
P/E Ratio
32.4
P/B Ratio
2.8
Industry P/E
40.89
EV/EBITDA
14.6
Div. Yield
1.1 %
Debt to Equity
0
Book Value
₹596.3
EPS
₹52.5
Face value
1
Shares outstanding
164,756,423
CFO
₹5,459.67 Cr
EBITDA
₹9,763.24 Cr
Net Profit
₹6,733.87 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gland Pharma
| -3.3 | -9.3 | 0.7 | 6.9 | 12.0 | -8.1 | -- |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Gland Pharma
| -4.9 | -6.7 | 22.1 | -59.2 | 63.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
|
1,664.8 | 27,406.4 | 6,112.8 | 847.2 | 17.2 | 9.2 | 32.4 | 2.8 |
| 17.0 | 24.5 | 83.7 | 2.1 | -- | 5.7 | 11.9 | 0.7 | |
| 700.3 | 1,266.5 | 77.0 | 16.4 | -- | 43.4 | 80.2 | 29.7 | |
| 87.0 | 31.7 | 54.6 | -1.1 | 3.6 | -3.5 | -- | 1.1 | |
| 64.5 | 32.5 | 150.3 | -2.2 | -0.6 | -4.8 | -- | 0.6 | |
| 17.5 | 15.3 | 6.7 | 0.3 | -- | 4.9 | 51.2 | 1.2 | |
| 177.0 | 972.3 | 264.6 | 19.3 | 8.9 | 6.2 | 41.9 | 4.2 | |
| 845.4 | 10,147.0 | 6,537.7 | 207.0 | 4.6 | 11.5 | 49 | 5.3 | |
| 155.1 | 83.0 | 61.7 | 6.3 | -- | 28.9 | 13.1 | 2.6 | |
| 116.4 | 42.8 | 20.6 | 2.5 | 18.7 | 16.9 | 17.2 | 2.6 |
3 min read•By Udhayaprakash
Gland Pharma IPO: Information Analysis
6 min read•By Danish Khanna
Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products... including synthesis of complex drug molecules, such as LMWH, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro intestinal, gynecological, hormones, neuro/Cns, ophthal/ontological, and other areas, as well as pain and analgesics, respirator, and vitamins, minerals and nutrients; and offers contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. Read more
Incorporated
1978
Chairman
Srinivas Sadu
Managing Director
--
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Gland Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Gland Pharma Ltd is ₹1,664.80 (NSE) and ₹1,663.45 (BSE) as of 18-Mar-2026 IST. Gland Pharma Ltd has given a return of 11.95% in the last 3 years.
The P/E ratio of Gland Pharma Ltd is 32.35 times as on 18-Mar-2026, a 21 discount to its peers’ median range of 40.89 times.
The P/B ratio of Gland Pharma Ltd is 2.79 times as on 18-Mar-2026, a 2 premium to its peers’ median range of 2.74 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
37.55
|
2.87
|
|
2024
|
39.27
|
3.48
|
|
2023
|
26.75
|
2.63
|
|
2022
|
44.33
|
7.52
|
|
2021
|
40.66
|
6.90
|
The 52-week high and low of Gland Pharma Ltd are Rs 2,131.00 and Rs 1,277.80 as of 19-Mar-2026.
Gland Pharma Ltd has a market capitalisation of ₹ 27,406 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Gland Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹30.90
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.